Skip to main content

Table 1 Clinical characteristics of the patient cohort

From: Efficiency of fluorodeoxyglucose positron emission tomography/computed tomography to predict prognosis in breast cancer patients received neoadjuvant chemotherapy

  Number %
Age
 Median 54  
 Range 30–75  
Tumor size
 Median 30  
 Range 13–120  
T status
 T1 8 9.6
 T2 62 74.7
 T3 7 8.4
 T4 6 7.2
N status
 N0 40 48.2
 N1 32 38.6
 N2 7 8.4
 N3 4 4.8
Stage before NAC
 Stage II 68 81.9
 Stage III 15 18.1
Type of surgery
 Breast-conserving surgery 38 45.8
 Mastectomy 36 43.4
 Skin-sparing mastectomy 8 9.6
 No operation 1 1.2
Type of axial surgery
 Sentinel lymph node biopsy 15 18.1
 Axial dissection after sentinel lymph node biopsy 4 4.8
 Axial dissection 63 75.9
 No operation 1 1.2
Subtype
 Luminal A and luminal B 54 65.1
 Luminal HER2 6 7.2
 HER2 positive 10 12.0
 Triple negative 13 15.7
Nuclear grade
 I 37 44.6
 II 20 24.1
 III 20 24.1
 Unknown 6 7.2
FDG uptake
 Negative 0 0.0
 Positive 83 100.0
Regimens of NAC
 wPAC → FEC 39 47.0
 DOC → FEC 39 47.0
 FEC → DOC 2 2.4
 FEC → DOC + H 1 1.2
 FEC → PTX + Bev 1 1.2
 wPAC 1 1.2
  1. PAC paclitaxel, FEC 5-FU, epirubicin and cycrophsphamide, DOC docetaxel, H trastuzumab, Bev bevacizumab